Having trouble accessing articles? Reset your cache.

Aranesp darbepoetin alfa: Additional Phase III data

Amgen previously reported that Aranesp missed the 2 composite co-primary endpoints of time to all-cause mortality or cardiovascular morbidity and time to all-cause mortality or chronic renal replacement therapy vs. placebo

Read the full 315 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE